Holen Sie sich die Stockscreener-App
31.65
2.25%
-0.73
Handel nachbörslich:
31.80
0.15
+0.47%
Schlusskurs vom Vortag:
$32.38
Offen:
$32.3
24-Stunden-Volumen:
3.03M
Relative Volume:
0.82
Marktkapitalisierung:
$3.58B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-34.03
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
-10.03%
1M Leistung:
-16.67%
6M Leistung:
+4.84%
1J Leistung:
-22.04%
1-Tages-Spanne:
$31.59
$32.30
1-Wochen-Bereich:
$31.56
$36.17
52-Wochen-Spanne:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Vergleichen Sie VKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
31.65 | 3.66B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Yahoo Finance
Viking Therapeutics (VKTX) Completes Enrollment for Key Metaboli - GuruFocus
Viking Therapeutics completes enrollment in obesity drug maintenance study By Investing.com - Investing.com Australia
Viking Therapeutics completes enrollment in obesity drug maintenance study - Investing.com
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity - PR Newswire
Viking Therapeutics: InvestingPro’s overvalued call proved right amid volatility By Investing.com - Investing.com Canada
Viking Therapeutics Charts Commercial Course with Key Appointment and Upcoming Investor Presentation - AD HOC NEWS
Viking Therapeutics Faces Headwinds Amid Commercial Push and Insider Sales - AD HOC NEWS
Will Viking Therapeutics’ New CCO Reframe VKTX’s Obesity Strategy Amid Intensifying GLP-1 Competition? - simplywall.st
Viking Therapeutics: A Tale of Strategic Hiring and Insider Sales - AD HOC NEWS
Viking Therapeutics Hires Neil Aubuchon as Chief Commercial Officer - Contract Pharma
Viking Therapeutics appoints Neil Aubuchon as chief commercial officer By Investing.com - Investing.com Nigeria
Viking Therapeutics appoints Neil Aubuchon as chief commercial officer - Investing.com India
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer - PR Newswire
Why Viking Therapeutics Stock Crashed Today - AOL.com
Viking Therapeutics (VKTX) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Viking Therapeutics Faces Scrutiny Amid Insider Sales and Key Industry Event - AD HOC NEWS
Here's What $100 Invested in Viking Therapeutics a Decade Ago Would Amount to Now - Bitget
Examining the Latest Short Interest in Viking Therapeutics Inc - Bitget
Looking Into Viking Therapeutics Inc's Recent Short Interest - Benzinga
Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms - Stocktwits
Insider Sales and Market Competition Weigh on Viking Therapeutics Shares - AD HOC NEWS
Insider Sell Alert: Matthew Foehr Sells 16,000 Shares of Viking Therapeutics Inc (VKTX) - GuruFocus
Viking Therapeutics Insider Sold Shares Worth $7,692,121, According to a Recent SEC Filing - MarketScreener
Viking Therapeutics Insider Sold Shares Worth $1,896,969, According to a Recent SEC Filing - MarketScreener
Leadership Stock Sales Cast Shadow Over Viking Therapeutics’ Prospects - AD HOC NEWS
What drives Viking Therapeutics Inc 1VT stock pricePrice Action Analysis & Low Risk Wealth Building - earlytimes.in
Viking Therapeutics stock suffers worst day in over 4 months as top execs dump shares — Novo’s $149 Wegovy move looms - MSN
Insider Selling: Viking Therapeutics (NASDAQ:VKTX) CEO Sells 233,409 Shares of Stock - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) CFO Sells $1,897,046.90 in Stock - MarketBeat
Marianna Mancini Sells 57,661 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock - MarketBeat
Viking Therapeutics CEO Lian sells $7.69m in shares By Investing.com - Investing.com Nigeria
Viking therapeutics COO Mancini sells $1.9 million in stock By Investing.com - Investing.com Nigeria
Viking Therapeutics CEO Lian sells $7.69m in shares - Investing.com
Viking therapeutics COO Mancini sells $1.9 million in stock - Investing.com
Viking Therapeutics director Foehr sells $561,694 in shares - Investing.com
Viking therapeutics CFO Zante sells $1.89m in shares By Investing.com - Investing.com UK
Viking Therapeutics director Foehr sells $561,694 in shares By Investing.com - Investing.com UK
A Look At Viking Therapeutics (VKTX) Valuation As Long Term Gains Contrast Recent Losses - simplywall.st
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - sharewise.com
Viking Therapeutics (NASDAQ:VKTX) Trading Down 6.1%What's Next? - MarketBeat
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing - TechStock²
$VKTX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today - AOL.com
Viking Therapeutics 2026: How Brian Lian Built a $4B Metabolic Fortress - CEO Today
How A Wall Street Analyst Started A $4 Billion Obesity Drug Company - Forbes
Viking Therapeutics Shares Consolidate as Investors Await Clinical Catalyst - AD HOC NEWS
Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics: A Tale of Clinical Momentum and Financial Strain - AD HOC NEWS
Could Viking Therapeutics Become the Next Eli Lilly? - MSN
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):